Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.

Abstract

ThyroidVol. 30, No. 4 Editorial and CommentariesTargeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized MedicineJoanna Klubo-Gwiezdzinska and Xiaoyuan ChenJoanna Klubo-GwiezdzinskaAddress correspondence to: Joanna Klubo-Gwiezdzinska, MD, PhD, MHSc, Thyroid Tumors and Functional Thyroid Disorders Section, Metabolic Disease Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10m room 9c103, Bethesda, MD 20892 E-mail Address: joanna.klubo-gwiezdzinska@nih.govThyroid Tumors and Functional Thyroid Disorders Section, Metabolic Disease Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.Search for more papers by this author and Xiaoyuan ChenMolecular Imaging and Nanomedicine Laboratory, National Institutes of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.Search for more papers by this authorPublished Online:15 Apr 2020https://doi.org/10.1089/thy.2020.0169AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byEvaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)19 December 2022 | Cancer Imaging, Vol. 22, No. 1Radiometal-theranostics: the first 20 years*24 November 2022 | Journal of Radioanalytical and Nuclear Chemistry, Vol. 132Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead12 July 2022 | Frontiers in Endocrinology, Vol. 13Investigation of the Presence of Integrin Alpha-3 and Beta-1 Receptors on Tumor Tissue, Metastatic Lymph Node and Normal Tissue in Thyroid Cancer1 June 2022 | Molecular Imaging and Radionuclide Therapy, Vol. 31, No. 2Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma29 April 2022 | Diagnostics, Vol. 12, No. 5Multimodal Imaging of Target Detection Algorithm under Artificial Intelligence in the Diagnosis of Early Breast CancerJournal of Healthcare Engineering, Vol. 2022Bioinspired peptide adhesion on Ti implants alleviates wear particle-induced inflammation and improves interfacial osteogenesisJournal of Colloid and Interface Science, Vol. 605Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery17 December 2021 | Pharmaceutics, Vol. 13, No. 12IVUS\IVPA hybrid intravascular molecular imaging of angiogenesis in atherosclerotic plaques via RGDfk peptide-targeted nanoprobesPhotoacoustics, Vol. 22 Volume 30Issue 4Apr 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Joanna Klubo-Gwiezdzinska and Xiaoyuan Chen.Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.Thyroid.Apr 2020.476-478.http://doi.org/10.1089/thy.2020.0169Published in Volume: 30 Issue 4: April 15, 2020Online Ahead of Editing: March 2, 2020PDF download